Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ragweed-SPIRE is an investigational immunotherapy product developed for the treatment of ragweed pollen allergy (seasonal allergic rhinitis). It is based on synthetic peptide immuno-regulatory epitopes (SPIREs) derived from the major allergen in ragweed pollen. The therapy aims to induce immune tolerance by targeting T-cell responses, thereby reducing allergic symptoms upon exposure to ragweed pollen. In clinical studies, Ragweed-SPIRE was administered as a short-course regimen prior to the start of the ragweed season and demonstrated dose-dependent improvements in allergy symptoms compared with placebo. The product was well-tolerated with no significant safety issues reported in trials[5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ragweed-spire.